Stock comparison
Genmab A/S
Grifols
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
GRFS
Grifols
Market cap
$6.75B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | GRFS | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 59D | GMAB |
| Benjamin Graham | 64C | 54C | GMAB |
| Philip Fisher | 48D | 50C | GRFS |
| Peter Lynch | 25F | 44D | GRFS |
| Joel Greenblatt | 76B | 26F | GMAB |
| Charlie Munger | 68C | 44D | GMAB |
| Terry Smith | 71C | 47D | GMAB |
Side-by-side metrics
| Metric | GMAB | GRFS |
|---|---|---|
| Market cap | $16.5B | $6.75B |
| P/E (TTM) | 6.2x | 14.9x |
| EV/EBIT | 12.0x | 12.8x |
| ROIC (TTM) | 43.78% | 5.49% |
| Gross margin | 93.88% | 37.68% |
| Net margin | 18.23% | 5.58% |
| Revenue CAGR 5y | -18.45% | 10.02% |
| EPS CAGR 5y | -23.48% | 20.54% |
| Debt / Equity | 0.1x | 1.8x |
| Dividend yield | 0.0% | 1.65% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 1.8x+96%
- ROIC (TTM)43.78%vs 5.49%+87%
- Net margin18.23%vs 5.58%+69%
- Gross margin93.88%vs 37.68%+60%
GRFS leads on
- EPS CAGR 5y20.54%vs -23.48%+187%
- Revenue CAGR 5y10.02%vs -18.45%+154%
- Dividend yield1.65%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.